定剂量米蒂格林因德/伏格利博斯组合和格利梅皮里德对2型糖尿病患者血管内皮功能和血糖变异性的比较影响:一项随机对照试验
Kenichi Tanaka1, Yosuke Okada1,2, Saeko Umezu1
1First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan.
Journal of diabetes investigation
|December 27, 2023
概括
在2型糖尿病患者中,米蒂格林因德/伏格利博斯降低了血糖变异性,食后高血糖和低血糖. 在这项短期研究中,这种联合治疗没有显著影响血管内皮功能.
科学领域:
- 内分泌学 在内分泌学.
- 药理学 药理学是指药理学的学科.
- 心血管医学 心血管医学
背景情况:
- 2型糖尿病的管理需要有效的策略来控制血糖的变化和维护血管内皮功能.
- 目前的治疗方法旨在改善血糖控制,但可能对这些关键参数产生不同的影响.
研究的目的:
- 为了比较mitiglinide/voglibose与glimepiride在2型糖尿病中控制血糖变异性和血管内皮功能方面的疗效.
- 评估这些治疗对血糖游览和内皮功能标志物的影响.
主要方法:
- 一个多中心的,开放的,随机的交叉研究,涉及30名住院的2型糖尿病患者.
- 患者接受了分别为5天的米蒂格林因德/伏格利博斯 (10mg/0.2mg三次) 或格利梅皮里德 (2mg四次) 治疗.
- 同主终点包括通过连续血糖监测的血管内皮功能反应性高血压指数 (RHI) 和血糖外流 (MAGE) 的平均幅度.
主要成果:
- 在mitiglinide/voglibose和glimepiride治疗之间没有观察到RHI的显著差异.
- 与glimepiride (100.6 mg/dL) 相比,使用mitiglinide/voglibose (47.6 mg/dL) 的MAGE显著较低.
- 米蒂格利尼德/伏格利博斯还显示平均葡萄糖,变化系数和平均食后葡萄糖外流的标准偏差较低,范围内的时间改善,范围以上/以下的时间减少.
结论:
- 在2型糖尿病患者中,Mitiglinide/voglibose在降低血糖变异性,包括食后高血糖和低血糖方面表现出显著的益处.
- 虽然在这个短期研究中没有影响血管内皮功能,但组合疗法对改善血糖控制有希望.
- 需要进一步的长期研究来证实这些发现,并评估更广泛的临床影响.
相关概念视频
Oral Hypoglycemic Agents: Biguanides and Glitazones
206
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
206
Dipeptidyl Peptidase 4 Inhibitors
188
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
188
Oral Hypoglycemic Agents: Glinides
156
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
156
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
177
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
177
Glucagon-like Receptor Agonists
325
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
325
Diabetes Mellitus: Type 2 and Gestational
2.4K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.4K


